Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
1.
Z Orthop Unfall ; 148(2): 180-4, 2010 Mar.
Artículo en Alemán | MEDLINE | ID: mdl-20135614

RESUMEN

STUDY AIM: Preoperative planning is regarded as an important requirement for successful implantation of a hip replacement. One of the crucial aspects of planning is the restoration of the normal anatomy of the hip as this increases the chances for good clinical function and reduces wear debris. Various systems for restoration of the hip are available including stem systems with different stem sizes and offsets and so-called modular stem systems which have the additional possibility of adjusting the neck length and angle. The aim of this study was to investigate to what extent a good postoperative outcome can be achieved using a modular and a non-modular stem system in comparison with preoperative planning. Furthermore, the study assessed the difference between preoperative planning carried out by a senior surgeon and by an assistant surgeon. METHOD: Standard preoperative and postoperative digitalised radiographs with an anteroposterior view of the pelvis centred over the pubic symphysis were made. Preoperative planning aimed for exact reconstruction of offset and equal leg length. Preoperative planning and evaluation of the postoperative outcome were performed by digitalised image-analysing software. The symptom-free contralateral hip served as reference for anatomic reconstruction. RESULTS: The postoperative results confirmed the preoperative planning. The preoperative planning was successfully implemented with both systems. Postoperatively, we observed a slightly reduced offset (Group 1: 3.6 mm, Group 2: 3.54 mm) and an increase in leg length of less than 5 mm in both groups. There was no significant difference between the preoperative planning carried out by the senior surgeon and the assistant surgeon. CONCLUSION: Implementation of preoperative planning with both the modular and the non-modular system was very satisfactory. It was irrelevant if the planning was carried out by a senior surgeon or by an assistant surgeon in the first year of training.


Asunto(s)
Artroplastia de Reemplazo de Cadera/métodos , Prótesis de Cadera , Procesamiento de Imagen Asistido por Computador/métodos , Cuidados Preoperatorios/métodos , Diseño de Prótesis , Intensificación de Imagen Radiográfica/métodos , Anciano , Anciano de 80 o más Años , Artroplastia de Reemplazo de Cadera/educación , Competencia Clínica , Gráficos por Computador , Femenino , Humanos , Internado y Residencia , Diferencia de Longitud de las Piernas/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/diagnóstico por imagen , Programas Informáticos
2.
BMC Cancer ; 1: 20, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11737874

RESUMEN

BACKGROUND: The effectiveness of neoadjuvant treatment (NT) prior to resection of squamous cell carcinoma of the esophagus (SCCE) in terms of prolonged survival has not been proven by randomized trials. Facing considerable financial expenses and with concerns regarding the consumption of the patient's remaining survival time, this study aims to provide rationales for pretreating resection candidates. METHODS: From March 1986 to March 1999, patients undergoing resection for SCCE were documented prospectively. Since 1989, NT was offered to patients with mainly upper and middle third T3 or T4 tumors or T2 N1 stage who were fit for esophagectomy. Until 1993, NT consisted of chemotherapy. Since that time chemoradiation has also been applied. The parameters for expense and benefit of NT are costs, pretreatment time required, postoperative morbidity and mortality, clinical and histopathological response, and actuarial survival. RESULTS: Two hundred and three patients were treated, 170 by surgery alone and 33 by NT + surgery. Postoperative morbidity and mortality were 52% to 30% and 12% to 6%, respectively (p = n.s.). The response to NT was detected in 23 patients (70%). In 11 instances (33%), the primary tumor lesion was histopathologically eradicated. Survival following NT + surgery was significantly prolonged in node-positive patients with a median survival of 12 months to 19 months (p = 0.0193). The average pretreatment time was 113 +/- 43 days, and reimbursement for NT to the hospital amounted to Euro 9.834. CONCLUSIONS: NT did not increase morbidity and mortality. Expenses for pretreatment, particularly time and costs, are considerable. However, taking into account that the results are derived from a non-randomized study, patients with regionally advanced tumor stages seem to benefit, as seen by their prolonged survival.


Asunto(s)
Carcinoma de Células Escamosas/tratamiento farmacológico , Carcinoma de Células Escamosas/cirugía , Quimioterapia/economía , Neoplasias Esofágicas/tratamiento farmacológico , Neoplasias Esofágicas/cirugía , Terapia Neoadyuvante/economía , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/radioterapia , Cisplatino/uso terapéutico , Terapia Combinada , Análisis Costo-Beneficio , Epirrubicina/uso terapéutico , Neoplasias Esofágicas/radioterapia , Esofagectomía/métodos , Femenino , Fluorouracilo/uso terapéutico , Humanos , Leucovorina/uso terapéutico , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante/métodos , Estadificación de Neoplasias/métodos , Estudios Prospectivos , Dosificación Radioterapéutica , Análisis de Supervivencia , Tomografía Computarizada por Rayos X/métodos
3.
Am J Clin Pathol ; 115(6): 835-40, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11392879

RESUMEN

Barrett esophagus (BE) is a condition in which the normal squamous epithelium of the esophagus is replaced by a metaplastic columnar epithelium. BE is a premalignant lesion that represents the initial step in a metaplasia-dysplasia-carcinoma sequence. In the present study, amplification of the proto-oncogene c-myc was determined by means of differential polymerase chain reaction analysis of metaplastic specialized epithelium, low-grade dysplasia, high-grade dysplasia, and invasive adenocarcinoma obtained by microscopic dissection of 43 esophagectomy specimens. Amplification of c-myc was found in none of 29 specialized epithelial specimens, none of 23 low-grade dysplasia specimens, 6 of 24 high-grade dysplasia specimens, and 17 of 39 adenocarcinoma specimens. Our data indicate that amplification of c-myc is a late event in the metaplasia-dysplasia-carcinoma sequence in BE. Furthermore, determination of c-myc amplification may help identify high-risk patients who would benefit from intensified endoscopic surveillance or from immediate treatment.


Asunto(s)
Adenocarcinoma/genética , Esófago de Barrett/genética , Neoplasias Esofágicas/genética , Amplificación de Genes , Genes myc , Adenocarcinoma/patología , Esófago de Barrett/patología , Progresión de la Enfermedad , Neoplasias Esofágicas/patología , Humanos , Proto-Oncogenes Mas
4.
Am J Clin Pathol ; 114(6): 890-5, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11338478

RESUMEN

Samples of Barrett metaplastic specialized epithelium (SE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and invasive adenocarcinoma (CA) derived from 36 esophagectomy specimens were studied for loss of heterozygosity (LOH) in APC and MCC and for expression of APC protein. Of 18 cases that were heterozygous (informative) for APC, LOH was found in none of 14 SE samples, 2 of 8 LGD samples, 3 of 11 HGD samples, and 5 of 17 CA samples. Immunohistochemically, markedly reduced expression of APC protein (< 50% positive cells) was found in 3 of 19 HGD samples and 4 of 35 CA samples but not in SE or LGD samples. Of 17 cases informative for the MCC gene, LOH was detectable in 1 of 14 SE samples, none of 7 LGD samples, none of 9 HGD samples, and 4 of 16 CA samples. Allelic loss of APC and/or loss of APC protein expression occurs earlier in the metaplasia-dysplasia-carcinoma sequence in Barrett esophagus than LOH in the MCC gene. The determination of alterations at APC or MCC would be of limited importance for the surveillance of patients with Barrett esophagus.


Asunto(s)
Adenocarcinoma/genética , Esófago de Barrett/genética , Neoplasias Esofágicas/genética , Genes APC , Genes MCC , Pérdida de Heterocigocidad , Lesiones Precancerosas/genética , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Proteína de la Poliposis Adenomatosa del Colon , Adulto , Anciano , Esófago de Barrett/metabolismo , Esófago de Barrett/patología , Proteínas del Citoesqueleto/metabolismo , Neoplasias Esofágicas/metabolismo , Neoplasias Esofágicas/patología , Femenino , Humanos , Inmunohistoquímica , Masculino , Metaplasia , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Lesiones Precancerosas/metabolismo , Lesiones Precancerosas/patología
5.
Cancer ; 86(12): 2597-601, 1999 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-10594854

RESUMEN

BACKGROUND: Barrett esophagus (BE) is a condition in which the normal squamous epithelium of the esophagus is replaced by metaplastic columnar epithelium. BE is a premalignant lesion because it is the initiating factor in a metaplasia-dysplasia-carcinoma sequence. METHODS: Expression of the proliferation-associated molecule cyclin E was immunohistochemically determined in metaplastic specialized epithelium (SE; n = 24), low grade dysplasia (LGD; n = 21), high grade dysplasia (HGD; n = 17), and invasive adenocarcinoma (CA; n = 35) from 36 esophagectomy specimens. In addition, endoscopically obtained samples of SE with minimal inflammatory changes (n = 11) and SE adjacent to erosions or ulcerations were tested for cyclin E expression. RESULTS: In the surgical specimens, expression of cyclin E was found in 0 of 24 SE (0%), 2 of 21 LGD (9.5%), 3 of 17 HGD (17.6%), and 5 of 35 CA (14. 3%). In the biopsy specimens, expression of cyclin E was found in all samples adjacent to erosions or ulcerations, whereas SE with minimal inflammatory changes was invariably negative for cyclin E. CONCLUSIONS: Accumulation of cyclin E can be found by means of immunohistochemistry in premalignant and malignant lesions in BE as well as in regenerative metaplastic epithelium. The determination of cyclin E expression is therefore not useful in the identification of BE patients with an increased risk for the development of carcinoma.


Asunto(s)
Esófago de Barrett/metabolismo , Carcinoma/metabolismo , Ciclina E/metabolismo , Neoplasias Esofágicas/metabolismo , Lesiones Precancerosas/metabolismo , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Adulto , Anciano , Anciano de 80 o más Años , Esófago de Barrett/patología , Carcinoma/patología , Neoplasias Esofágicas/patología , Femenino , Humanos , Inmunohistoquímica , Masculino , Metaplasia/metabolismo , Persona de Mediana Edad , Lesiones Precancerosas/patología
6.
Int J Cancer ; 84(6): 618-22, 1999 Dec 22.
Artículo en Inglés | MEDLINE | ID: mdl-10567909

RESUMEN

The retinoblastoma gene (RB) is a typical tumor-suppressor gene. Inactivation of RB has been shown in a variety of human cancers, including esophageal squamous-cell carcinomas. In the present study, samples of normal esophageal squamous epithelium (n = 10), severe squamous-cell dysplasias (n = 19), carcinomas in situ (n = 14), invasive squamous-cell carcinomas (n = 172), and 2 continuous esophageal-carcinoma cell lines were immunohistochemically analyzed for pRb expression. The specificity of immunostaining was tested by Western-blot analysis of pRb expression in the cell lines. In normal esophageal epithelium, nuclear pRb expression was restricted to the parabasal cell layer, whereas, in a considerable portion of severe dysplasias and carcinomas in situ, pRb over-expression was found. Among carcinomas, 161 of 172 cases showed pRb expression, as did the 2 esophageal-carcinoma cell lines, whereas 11 carcinomas were negative. Expression of pRb among carcinomas was not correlated with pT category, pN category or tumor grade. In the univariate survival analysis, patients with pRb-negative tumors showed lower 2-year and 5-year survival rates (27.3%/9.1%) than patients with pRb-positive tumors (42.8%/25.8%; not significant). In conclusion, pRb protein can be detected by immunohistochemistry in a high percentage of squamous-cell carcinomas of the esophagus and its precursor lesions. However, expression of the pRb protein has no significant impact on the prognosis. Int. J. Cancer (Pred. Oncol.) 84:618-622, 1999.


Asunto(s)
Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/metabolismo , Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/metabolismo , Proteína de Retinoblastoma/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Western Blotting , Carcinoma in Situ/metabolismo , Carcinoma de Células Escamosas/mortalidad , Carcinoma de Células Escamosas/patología , Supervivencia sin Enfermedad , Neoplasias Esofágicas/mortalidad , Neoplasias Esofágicas/patología , Esófago/metabolismo , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Membrana Mucosa/metabolismo , Lesiones Precancerosas/diagnóstico , Lesiones Precancerosas/metabolismo , Pronóstico , Tasa de Supervivencia , Factores de Tiempo , Células Tumorales Cultivadas
7.
Am J Pathol ; 155(4): 1027-32, 1999 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-10514383

RESUMEN

Basaloid squamous cell carcinoma (BSCC) of the esophagus is a rare, poorly differentiated variant of typical esophageal squamous cell carcinoma (SCC) characterized by high proliferative activity and frequent spontaneous apoptoses. In the present study, we investigated the expression of the apoptosis-suppressing protein Bcl-2 in 23 BSCC of the esophagus and 23 stage-matched typical esophageal SCC by means of immunohistochemistry. In addition, amplification of the apoptosis- and proliferation-inducing gene c-myc was determined by means of differential polymerase chain reaction. Bcl-2 expression was found significantly more often in BSCC than in SCC (86.9% vs. 17.4%, P < 0.0001). Amplification of c-myc was nearly twice as common in BSCC as in SCC (47.8% vs. 26.1%, not significant). Bcl-2 protein expression together with c-myc amplification was detected in 43.5% of the BSCC but in none of the typical SCC (P < 0.0001). Taken together, our findings indicate that the molecular pathogenesis of esophageal BSCC differs from that of typical SCC and frequently involves coactivation of c-myc and Bcl-2.


Asunto(s)
Carcinoma Basoescamoso/metabolismo , Carcinoma de Células Escamosas/metabolismo , Neoplasias Esofágicas/metabolismo , Genes myc/genética , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Adulto , Anciano , Carcinoma Basoescamoso/genética , Carcinoma de Células Escamosas/genética , Neoplasias Esofágicas/genética , Esófago/metabolismo , Femenino , Amplificación de Genes , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa
8.
Int J Cancer ; 84(1): 86-91, 1999 Feb 19.
Artículo en Inglés | MEDLINE | ID: mdl-9988238

RESUMEN

In the present study, the expression of cyclin D1, as detected by immunohistochemistry, was compared with other prognostic variables and its prognostic impact was evaluated in a group of 172 patients with squamous cell carcinoma (SCC) of the esophagus who underwent potentially curative resection therapy and in a second group of 38 patients with SCC of the esophagus who were treated by combined modality therapy (radiochemotherapy +/- surgery). Expression of cyclin D1 in surgically treated carcinomas correlated negatively with tumor differentiation (p = 0.026) but positively with mitotic activity (p = 0.0199) and nodal status (p = 0.040). There were no significant correlations with pT category. Patients with cyclin D1-positive carcinomas showed significantly worse overall survival than patients with cyclin D1-negative carcinomas, both in univariate (p = 0.0016) and in multivariate survival analyses (p = 0.0038). Expression of cyclin D1 in carcinomas with multimodal treatment was correlated with poor response to chemotherapy (p = 0.026) but not with overall survival. We thus consider expression of cyclin D1 to be an important parameter, predicting an unfavorable overall survival of surgically treated esophageal cancer patients.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/metabolismo , Ciclina D1/biosíntesis , Neoplasias Esofágicas/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/biosíntesis , Carcinoma de Células Escamosas/mortalidad , Carcinoma de Células Escamosas/cirugía , Carcinoma de Células Escamosas/terapia , Cisplatino/administración & dosificación , Terapia Combinada , Epirrubicina/administración & dosificación , Neoplasias Esofágicas/mortalidad , Neoplasias Esofágicas/cirugía , Neoplasias Esofágicas/terapia , Esófago/metabolismo , Femenino , Fluorouracilo/administración & dosificación , Humanos , Leucovorina/administración & dosificación , Masculino , Persona de Mediana Edad , Membrana Mucosa/metabolismo , Pronóstico , Tasa de Supervivencia
9.
Clin Cancer Res ; 4(11): 2615-23, 1998 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-9829724

RESUMEN

The p21WAF1 protein is an important regulator of the cell cycle. Its expression and prognostic significance were investigated immunohistochemically in samples of normal esophageal squamous epithelium (n = 10), severe squamous cell dysplasia (n = 20), carcinoma in situ (n = 14), permanent esophageal squamous cell carcinoma cell lines (n = 3), and invasive squamous cell carcinomas treated either by potentially curative resection (n = 172) or by combined modality therapy (radiochemotherapy +/- surgery; n = 38). Whereas p21WAF1 expression in the normal epithelium was restricted to a few cells adjacent to the basal cell layer, p21WAF1 overexpression was frequently found in preneoplasias and invasive carcinomas. Expression of p21WAF1 in invasive carcinomas was not correlated with tumor differentiation, pT category, or pN category. Among carcinomas treated by potential curative resection, univariate (P = 0.0025) and multivariate (P = 0.0081) survival analysis showed significant correlation of strong p21WAF1 expression (> or =50% p21WAF1-positive tumor cells) with poor overall survival. Univariate survival analysis (P = 0.0006) revealed the same prognostic influence in the group of patients treated by combined modality therapy. We conclude that overexpression of p21WAF1 protein is a frequent event in preneoplasias and neoplasias of the esophagus. Immunohistochemical examination of p21WAF1 expression may provide important prognostic information for decision-making in the treatment of patients with esophageal cancer.


Asunto(s)
Carcinoma in Situ/metabolismo , Carcinoma de Células Escamosas/metabolismo , Ciclinas/biosíntesis , Neoplasias Esofágicas/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Western Blotting , Carcinoma in Situ/diagnóstico , Carcinoma in Situ/cirugía , Carcinoma in Situ/terapia , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/cirugía , Carcinoma de Células Escamosas/terapia , Terapia Combinada , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/cirugía , Neoplasias Esofágicas/terapia , Esófago/citología , Esófago/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Membrana Mucosa/metabolismo , Invasividad Neoplásica , Pronóstico , Estudios Retrospectivos , Análisis de Supervivencia , Células Tumorales Cultivadas
10.
Clin Cancer Res ; 4(3): 577-83, 1998 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9533524

RESUMEN

Bcl-X, a Bcl-2-related protein, is a potent antagonist of apoptosis in its long splice variant (Bcl-X(L)). The present study was performed to determine its expression in preneoplastic and neoplastic lesions of the esophagus, its correlation with other members of the Bcl-2 family, and its impact on the outcome of surgically treated esophageal cancer patients. Samples of normal esophageal squamous epithelium (n = 10), severe squamous cell dysplasias (n = 19), carcinomas in situ (n = 14), invasive squamous cell carcinomas (n = 172), and lymph node metastases (n = 21) were immunohistochemically analyzed for Bcl-X(L) expression using a polyclonal anti-Bcl-X(L) antibody. The immunostaining was evaluated according to a score system (0-12 points) based on the percentage of positive tumor cells and the relative immunostaining intensity. Cytoplasmic staining for Bcl-X(L) protein was invariably found in all cell layers of the normal esophageal squamous epithelium. In contrast, a considerable portion of preneoplastic and neoplastic lesions display a decreased Bcl-X(L) expression as compared with that in the normal esophageal epithelium. On comparison of the amount of Bcl-X(L) expression between the different types of lesions, however, no significant differences were found between severe squamous cell dysplasias (mean immunoreactive score +/- SD, 5.2 +/- 1.8), carcinomas in situ (5.2 +/- 2.2), invasive carcinomas (4.5 +/- 2.8), and lymph node metastases (4.2 +/- 2.6). In invasive carcinomas, Bcl-X(L) expression decreased continuously with decreasing tumor differentiation (P = 0.0001) and was also directly correlated with bcl-2-associated X protein expression (P = 0.0001). On the contrary, an inverse correlation was found between Bcl-X(L) expression and Bcl-2 protein expression (P = 0.0001). No correlation was found between Bcl-X(L) expression and the parameters pT category, pN category, and tumor size. In the univariate survival analysis, patients with low immunoreactive scores (< or = 4) of Bcl-X(L) expression in the tumor tissue showed lower 2-year and 5-year survival rates than patients with high immunoreactive scores (> 4; P = 0.0485). In multivariate survival analysis, however, only the parameters pN category and pT category, but not Bcl-X(L) expression, could be verified as independent prognostic factors. This tendency of decreasing levels of an antiapoptotic protein toward unfavorable outcome is supported by an increasing number of studies on the role of Bcl-2, another antiapoptotic protein, and must be interpreted against the backdrop of apoptosis as a result of the interaction of many cell death-promoting and protecting proteins.


Asunto(s)
Carcinoma de Células Escamosas/patología , Neoplasias Esofágicas/patología , Lesiones Precancerosas/patología , Proteínas Proto-Oncogénicas c-bcl-2/análisis , Apoptosis , Carcinoma in Situ/mortalidad , Carcinoma in Situ/patología , Carcinoma in Situ/cirugía , Carcinoma de Células Escamosas/mortalidad , Carcinoma de Células Escamosas/cirugía , Neoplasias Esofágicas/mortalidad , Neoplasias Esofágicas/cirugía , Esófago/citología , Esófago/patología , Humanos , Inmunohistoquímica , Metástasis Linfática , Membrana Mucosa/citología , Membrana Mucosa/patología , Invasividad Neoplásica , Lesiones Precancerosas/mortalidad , Lesiones Precancerosas/cirugía , Pronóstico , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Valores de Referencia , Tasa de Supervivencia , Factores de Tiempo , Proteína bcl-X
11.
Cancer ; 79(10): 1871-8, 1997 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-9149011

RESUMEN

BACKGROUND: Basaloid squamous cell carcinoma (BSCC) is a recently recognized, poorly differentiated variant of squamous cell carcinoma (SCC), which is located predominantly in the upper aerodigestive tract. METHODS: In this study, clinical and pathologic parameters of 17 BSCCs and 133 typical SCCs of the esophagus that underwent potentially curative resection (no distant metastases, no residual tumor) were compared. In addition, light microscopic, electron microscopic, and immunohistochemical features of BSCC were investigated, to determine whether this type of carcinoma could be differentiated from other poorly differentiated carcinomas of the esophagus. RESULTS: Light microscopic study showed that BSCC was composed of relatively small tumor cells, arranged in solid lobules with abundant comedo-type necrosis. BSCC was almost invariably accompanied by areas of concomitant typical SCC, foci of squamous cell differentiation, and/or severe squamous cell dysplasia or carcinoma in situ of the adjacent mucosa. Ultrastructurally, BSCC inconsistently showed features of squamous cell differentiation. Immunohistochemically, BSCC displayed poor reactivity for antibodies against wide-range cytokeratins and cytokeratin subtypes that are typical of squamous cell epithelia (cytokeratin 13 and cytokeratin 14). Infrequently, expression of Leu7, smooth muscle actin, and S-100 protein was found. In comparison with typical SCC, the characteristic features of BSCC were older patient age, higher proliferative activity (MIB-1 labelling index), and higher apoptotic indices. No differences were found with regard to pT classification, pN classification, tumor size, blood vessel invasion, lymphatic vessel invasion, neural invasion, or patient gender. Moreover, no differences in overall survival rates were found. CONCLUSIONS: BSCC is a distinct histopathologic variant of SCC, characterized by a poor degree of differentiation and high proliferative activity. However, after potentially curative resection, the prognosis of patients with BSCC of the esophagus does not differ from that of patients with typical SCC.


Asunto(s)
Carcinoma Basoescamoso/diagnóstico , Carcinoma de Células Escamosas/diagnóstico , Neoplasias Esofágicas/diagnóstico , Actinas/análisis , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Antígenos de Diferenciación/análisis , Apoptosis , Carcinoma in Situ/patología , Carcinoma Basoescamoso/patología , Carcinoma Basoescamoso/cirugía , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/cirugía , Diferenciación Celular , División Celular , Diagnóstico Diferencial , Epitelio/patología , Neoplasias Esofágicas/patología , Neoplasias Esofágicas/cirugía , Femenino , Humanos , Inmunohistoquímica , Queratinas/análisis , Masculino , Microscopía Electrónica , Persona de Mediana Edad , Membrana Mucosa/patología , Necrosis , Invasividad Neoplásica , Estadificación de Neoplasias , Pronóstico , Proteínas S100/análisis , Factores Sexuales , Tasa de Supervivencia
12.
Clin Cancer Res ; 3(12 Pt 1): 2263-8, 1997 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9815623

RESUMEN

In the present study, urokinase-type plasminogen activator (uPA) expression in 150 potentially curatively resected SCCs of the esophagus was analyzed immunohistochemically by means of a murine monoclonal antibody (American Diagnostica, Greenwich, CT) and correlated with survival. Altogether, 122 of the 150 tumors (81.3%) expressed different levels of uPA. Among the 122 uPA-positive tumors, 104 (85.2%) showed a weak staining intensity, and 18 (14.8%) showed a strong staining intensity. Among the uPA-positive tumors, 29 (23. 8%) tumors showed a uPA immunoreactivity in 6-25% of all tumor cells, 30 (24.6%) showed a uPA immunoreactivity in 26-50% of all tumor cells, 41 (33.6%) showed a uPA immunoreactivity in 51-75% of all tumor cells, and 22 (18.0%) showed a uPA immunoreactivity in 76-100% of all tumor cells. No significant correlation could be shown between the different patterns of uPA expression and various clinicopathological parameters, such as pT category, pN category, tumor size, histological grade, blood vessel invasion, lymphatic vessel invasion, and inflammatory response. Concerning the overall postoperative survival, no significant differences between uPA-positive and uPA-negative tumors could be verified. This also held true when different cut points in the percentage of uPA-positive tumor cells were used. In contrast, the intensity of uPA staining provided significant prognostic information in that patients with strongly uPA-positive tumors had a poorer outcome than patients with weakly uPA-positive or uPA-negative tumors. Moreover, as shown by stepwise multivariate Cox regression analysis, the intensity of uPA expression was an independent prognostic factor.


Asunto(s)
Carcinoma de Células Escamosas/patología , Neoplasias Esofágicas/patología , Activador de Plasminógeno de Tipo Uroquinasa/análisis , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales , Carcinoma de Células Escamosas/enzimología , Carcinoma de Células Escamosas/mortalidad , Carcinoma de Células Escamosas/cirugía , Citoplasma/enzimología , Citoplasma/patología , Supervivencia sin Enfermedad , Neoplasias Esofágicas/enzimología , Neoplasias Esofágicas/mortalidad , Neoplasias Esofágicas/cirugía , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Inflamación , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Análisis de Supervivencia , Factores de Tiempo , Activador de Plasminógeno de Tipo Uroquinasa/genética
13.
Anticancer Res ; 17(5B): 3915-9, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9427803

RESUMEN

EGFR expression in 150 potentially curative resected squamous cell carcinomas of the oesophagus was analyzed immunohistochemically and correlated with survival. Altogether, 124 of 150 (82.7%) tumours expressed different levels of EGFR. The percentage of tumour cells expressing EGFR varied greatly between the different tumours (median: 70%). 62 (50.0%) tumours showed weak and intense staining, respectively. Regarding the staining pattern 19 (15.3%) tumours showed exclusively membraneous immunoreactivity, 27 (21.8%) an exclusively cytoplasmic immunoreactivity and 78 (62.9%) a mixed staining pattern. No significant correlation however could be found between EGFR expression and various clinicopathologic parameters such as pT category, pN category, tumour size, histologic grade and blood vessel invasion. In univariate survival analysis, no correlation between EGFR expression and postoperative survival time was observed. In a forward multivariate Cox regression analysis only the parameters lymphatic-vessel invasion (p = 0.001), pT category (p = 0.0034) and pN category (p = 0.0256), but not the EGFR expression, could be verified as independent prognostic variables. In conclusion, the evaluation of the EGFR expression does not provide prognostic information for patients who underwent potentially curative resection for SCC of the oesophagus.


Asunto(s)
Carcinoma de Células Escamosas/química , Carcinoma de Células Escamosas/mortalidad , Receptores ErbB/análisis , Neoplasias Esofágicas/química , Neoplasias Esofágicas/mortalidad , Proteínas de Neoplasias/análisis , Adulto , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Carcinoma de Células Escamosas/patología , Neoplasias Esofágicas/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Análisis de Supervivencia
14.
J Homosex ; 30(1): 75-87, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-8907599

RESUMEN

Traditional scholarship deliberately avoids homosexism, a scholarly approach offering the opportunity for a homosexual reading, in Frank O'Hara's poetry. As a member of the New York City Movement, O'Hara breaks with conventional poetic and social conventions, discussing homosexuality as a natural form of social interaction. This essay, by way of an intrinsic approach, closely examines homosexual subtexts in his poetry in general, and in the poem "A Step Away From Them" in particular.


Asunto(s)
Homosexualidad Masculina , Literatura Moderna , Poesía como Asunto , Personajes , Historia del Siglo XX , Humanos , Masculino , Ciudad de Nueva York , Estados Unidos
16.
Rontgenblatter ; 43(11): 455-6, 1990 Nov.
Artículo en Alemán | MEDLINE | ID: mdl-2277922

RESUMEN

The chest x-ray film of a 33-year-old man revealed circular densities which were suspected to be metastases combined with hilar and mediastinal lymphadenopathies. Histology of a paratracheal lymph node gave the diagnosis sarcoidosis. Nine months later the intrapulmonary densities had disappeared. Radiological findings are now stage II sarcoidosis.


Asunto(s)
Enfermedades Pulmonares/diagnóstico por imagen , Sarcoidosis/diagnóstico por imagen , Adulto , Humanos , Masculino , Radiografía Torácica
20.
Rofo ; 130(4): 420-2, 1979 Apr.
Artículo en Alemán | MEDLINE | ID: mdl-155595

RESUMEN

No differences could be detected subjectively in the quality of cholangiograms after the use of varying amounts of contrast medium (20 and 30 ml iodoxaminic acid). Pharmacolinetic data which would indicate the use of either quantity are not available. Densitometric measurements carried out by us showed no significant statistical difference between the results of using 20 or 30 ml iodoxaminic acid.


Asunto(s)
Colecistografía , Conducto Colédoco/diagnóstico por imagen , Medios de Contraste/administración & dosificación , Densitometría , Humanos , Ácidos Triyodobenzoicos/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA